AUTONOMIX MEDICAL INC

Company Overview

Autonomix Medical is a development-stage medical device company building a catheter-delivered, microchip-enabled neural sensing and RF ablation platform, initially targeted at palliative pain management for pancreatic and other visceral cancers. The technology couples a multi-spline electrode “antenna” with on-board amplification/digitization and the company plans first-in-human device availability in 2026 with commercial scale-up targeted by mid-2027. Operations are small and R&D-intensive (11 employees plus contractors), with hand-built prototypes transitioning to contract manufacturing, a substantive patent portfolio (18 families; ~86 issued patents), and a cash runway into Q1–Q2 2026 absent additional financing. The business is highly dependent on clinical outcomes, FDA interactions (De Novo pathway expected), third‑party manufacturing and successful scale-up, with an estimated $32–$40M needed to reach initial commercial launch.

Executive Compensation Practices

Given the development-stage profile and constrained cash runway, executive pay at Autonomix is equity‑heavy and milestone‑oriented: management has disclosed rising stock‑based compensation and uses warrants/inducement instruments to conserve cash while aligning incentives to clinical and regulatory milestones (PoC1/PoC2, GLP data, U.S. EFS). GAAP results are volatile because of non‑cash items (stock compensation, warrant accounting) so cash compensation is likely moderated while long‑term incentives dominate. The company also carries contingent severance obligations (~$1.1–$1.7M) for key employees, indicating retention provisions that are material for a small team. Expect future compensation packages to continue leaning on equity, performance vesting, and potential licensing/success bonuses as fundraising and regulatory progress unfold.

Insider Trading Considerations

Insider transaction patterns at Autonomix are likely to cluster around discrete, material events—clinical readouts (e.g., PoC1/PoC2 results), FDA interactions and patent issuances—so filings around those dates can carry informational value. Recent corporate actions (ATM activity, a July 2025 warrant exercise inducement, cancellation of options and issuance of inducement warrants) increase the frequency of equity grants/exercises and potential dilution; monitor insider option/warrant exercises and the timing of any open‑market sales tied to financings. Because the company is small, with concentrated insider holdings and low float, even modest insider buys or sells can move the stock; insiders should be expected to use equity instruments rather than cash pay, and trading will be constrained by securities laws, company blackout policies, and sensitivity around nonpublic clinical/regulatory information.